TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients With Hepatocellular Carcinoma

Más betegség

• Patients diagnosed with a cancer other than HCC within 2 years of enrollment.
• Patients for whom the use of idarubicin or doxorubicin is contraindicated (including severe heart failure, arrhythmia, hypersensitivity to anthracycline chemotherapy, pregnant or nursing women, etc.).

Egyéb

• Patients with HCC involving the portal vein or hepatic vein.
• Patients with extrahepatic spread of HCC
• Patients who have undergone a biliary-intestinal anastomosis.

• Adults aged 19 or above.
• Patients diagnosed with HCC either histologically and/or radiologically (LI-RADS 4 or 5).
• Patients with five or fewer tumors.
• Patients in which the largest tumor is 5 cm or less in diameter.
• Patients with no prior treatment experience for HCC.
• Patients categorized as Child-Pugh class A or B.
• Patients with an Eastern Cooperative Oncology Group performance status of 2 or below.
• Patients without severe functional abnormalities of major organs: the following results from a blood test conducted within a month prior to the procedure must be satisfied:
  • WBC count ≤ 12,000 / mm3
  • Absolute neutrophil count ≥ 1,500 /mm3
  • Hemoglobin ≥ 8.0 g/dL
  • Total bilirubin ≤ 3.0 mg/dL
  • eGFR ≥ 30 mL/min/1.73 m2
  • Patients deemed clinically most suitable to receive TACE through hepatologist, hepatic surgeon, or multidisciplinary consultation: patients for whom other treatments such as liver transplantation/surgery/ablation are realistically impossible or, even if technically possible, do not have significant clinical benefits compared to TACE.
  • Patients who have understood sufficiently about this clinical trial and have given written consent to participate.
  • Fertile women capable of effective contraception for at least 6.5 months after TACE, and men with fertile female partners capable of effective contraception for at least 3.5 months after TACE.